Photos Snapped During FDA Device Inspections: Fair Game Or Agency Overreach?
This article was originally published in The Gray Sheet
FDA says it has the authority to take photographs during facility inspections, citing decades-old non-medical-device-related legal cases as evidence – including Dow Chemical Co. v. US – but industry lawyer Robert Klepinski says FDA's reliance on the Dow case as a defense for snapping pictures doesn't pass muster. "The agency always cites the Dow Chemical case, wherein the EPA flew over [Dow's plant] with a helicopter or airplane and took pictures," Klepinski said, noting that "it’s absolutely ludicrous, a stupid case to cite" because FDA investigators don't inspect device firms from the air. Meanwhile, the agency doesn't have a policy in place that addresses investigators' personal cameras, such as phone cameras, which throws into question whether photos could unintentionally – or intentionally – fall into third-party hands. Also, device-maker Cynosure's VP of regulatory affairs, Connie Hoy, talks about how her company handles photo requests made by investigators.
You may also be interested in...
On this week’s podcast we talk about outgoing US FDA chief Stephen Hahn and the role he wants to play beyond 20 January, as an ex-commissioner. We also discuss the US enforcement landscape around COVID-19-related products and how it’s still taking shape.
A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.
The US agency announced on 11 January a recall of the Lotus Edge transcatheter aortic valve replacement (TAVR) system – a device that Boston Scientific stopped making and voluntarily recalled two months ago.